Compare WVE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | MDXG |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | 808 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.8M | 672.8M |
| IPO Year | 2015 | 2007 |
| Metric | WVE | MDXG |
|---|---|---|
| Price | $3.45 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $18.06 | $7.40 |
| AVG Volume (30 Days) | ★ 2.9M | 965.8K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $3,704,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | N/A | $21.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 149.43 | 19.99 |
| 52 Week Low | $3.43 | $3.03 |
| 52 Week High | $21.73 | $7.97 |
| Indicator | WVE | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 49.65 |
| Support Level | N/A | $4.37 |
| Resistance Level | $6.33 | $4.76 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 8.56 | 33.90 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.